Flavopiridol (Alvocidib)

Catalog No.S1230 Synonyms: NSC 649890 HCl,HMR-1275

Flavopiridol (Alvocidib) Chemical Structure

Molecular Weight(MW): 401.84

Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) After mitotic arrest and treatment with the proteasome inhibitor MG132, HeLa cells were treated with the indicated kinase inhibitors The cells were harvested, and the lysates were separated by SDS-PAGE and immunoblotted for phosphorylated RV[S/T]F (p-RV[S/T]F, top). The blot was quantified using ImageJ software and normalized to the mitotic sample (bottom). MLN8054, Aurora A and Aurora B inhibitor; ZM447439 and hesperadin, Aurora B inhibitors; BI2536, PLK1 inhibitor; flavopiridol, CDK1 inhibitor. n = 3. **P < 0.01, paired Student’s t test.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. Flavopiridol (Alvocidib) purchased from Selleck.

    (C) In vivo treatment of Tg:Pomc-Pttg;Pomc-eGFP embryos with small-molecule CDK inhibitors (50 μM) or 0.2% DMSO as control from 18 to 40 hpf. One hundred to one hundred fifty embryos were treated with each compound. Representative images of live embryos are shown with gross morphology (Right) and pituitary Pomc-GFP-positive cells at higher magnification (Left) at 40 hpf. Embryos exposed to flavopiridol developed early developmental defect before pituitary POMC cell ontogeny occurs. (D) Relative expression of pituitary Pomc-eGFP fluorescence analyzed using Volocity 5.2 software (Improvision; mean ±SE of relative expression, n = 7). (E) R-roscovitine specifically suppresses expansion of pituitary POMC cells overexpressing zPttg from 18 to 48 hpf. Double transgenic Tg:Pomc-Pttg;Prl-RFP embryos were generated by breeding Tg:Pomc-Pttg fish with a previously generated PRL-RFP transgenic line, in which RFP was targeted to pituitary lactotrophs by a zebrafish Prolactin promoter (34). Representative fluorescent microscopy of pituitary POMC-eGFP (a and b) and PRL-RFP (c and d) expression in live Tg:Pomc-Pttg; Pomc-eGFP and Tg:Pomc-Pttg;Prl-RFP embryos treated with 0.2% DMSO (a and c) or 50 μM R-roscovitine (b and d). (F) Relative expression of pituitary POMC-eGFP or PRL-RFP fluorescence were analyzed (mean ±SE of relative expression; n = 10). Results represent one of three similar experiments;*P < 0.02 and **P < 0.000005. (Scale bar, 50 μm.)

    PNAS 2011 108, 8417. Flavopiridol (Alvocidib) purchased from Selleck.

  • G, human THP-1 cells were treated with various small-molecule inhibitors or chemotherapy at increasing concentrations for 24 hours and then analyzed for viability by flow cytometry for PI exclusion. Cells concurrently treated with palbociclib or dinaciclib were analyzed for cytostatis according to nuclear DNA content.

    Cancer Res, 2016, 76(5):1158-69. Flavopiridol (Alvocidib) purchased from Selleck.

    UM cell lines OMM1, MM66, OMM2.3, MEL202 and MEL270 were treated with 20 nM quisinostat and 100 nM flavopiridol for 24 hours after which cells were harvested. Protein lysates were analyzed for the expression levels of c-Myc, RNA pol2-CTD Ser2 phosphorylation and acetylated histone 3 by Western blot. Expression of vinculin was analyzed to control for equal loading.

    Oncotarget, 2018, 9(5): 6174-6187. Flavopiridol (Alvocidib) purchased from Selleck.

  • Pharmacological inhibition of either CDK1/2 or E2F1 prevented the induction of the expression of MAD2 by SKP2 overexpression. Notes: (A) Human lung cancer A549 cells were transfected with 2 μg of vector pcDNA3.1 or pcDNA-SKP2 for 48 h, then treated with CDK1/2 inhibitor flavopiridol or E2F1 inhibitor HLM006474 for additional 24 h. Total RNAs were extracted for the detection of the mRNA levels MAD2 by RT-QPCR with GAPDH as internal control. Quantitative analysis are expressed as mean ± SEM. n=3, *P<0.05 vs control. (B) Human lung cancer A549 cells were transfected with 2 μg of vector pcDNA3.1 or pcDNA-SKP2 for 48 h, then treated with CDK1/2 inhibitor flavopiridol or E2F1 inhibitor HLM006474 for additional 24 h. Total proteins were extracted for the detection of the protein levels Skp2 and Mad2 and the phosphorylation of Rb at Ser780 (pRb-S780) by Western blotting. GAPDH served as the loading control. (C) Human lung cancer A549 cells were transfected with 50 nM control or SKP2-specific siRNA with lipofectamine 2000 for 48 h, then treated with CDK1/2 inhibitor flavopiridol or E2F1 inhibitor HLM006474 for additional 24 h. Total proteins were extracted for the detection of the protein levels Skp2 and Mad2 by Western blotting. GAPDH served as the loading control. Abbreviations: MAD2, mitotic arrest deficient 2; SKP2, S-phase kinase-associated protein 2; mRNA, messenger RNA; SEM, standard error of the mean; Rb, retinoblastoma; siRNA, small interfering RNA.

    Onco Targets Ther, 2017, 10:439-446. Flavopiridol (Alvocidib) purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Features First CDK inhibitor to be used in human clinical trials.
Targets
CDK9 [8]
(Cell-free assay)
CDK1 [8]
(Cell-free assay)
CDK4 [9]
(Cell-free assay)
CDK2 [8]
(Cell-free assay)
CDK6 [9]
(Cell-free assay)
20 nM 30 nM 20-40 nM 40 nM 60 nM
In vitro

Flavopiridol displays less activity against unrelated kinases such as MAP, PAK, PKC, and EGFR with IC50 of >14 μM. Flavopiridol significantly inhibits the colony growth of HCT116, A2780, PC3, and Mia PaCa-2 cells with IC50 of 13 nM, 15 nM, 10 nM and 36 nM, respecitively. [1] Flavopiridol also potently inhibits the activity of Glycogen synthase kinase-3 (GSK-3) with an IC50 of 280 nm. [2] Compared with other CDKs, Flavopiridol inhibits the activity of CDK7 less potently with IC50 of 875 nM. Flavopiridol (0.5 μM) inhibits both pSer807/811 Rb and pThr199 NPM, whereas mild changes are observed at pThr821 Rb. Flavopiridol also decreases the overall RNA polymerase II level, as well as the phosphorylation of RNA polymerase II on the CTD repeats at Ser2 Ser5. [3] As a broad spectrum CDK inhibitor, Flavopiridol can inhibit cell cycle progression in either G1 or G2. Flavopiridol (0.3 μM) induces G1 arrest in either MCF-7 or MDA-MB-468 cells by inhibition of the CDK4 or CDK2 kinase activity. [4] Flavopiridol exhibits potent cytotoxicity against a wide variety of tumor cell lines with IC50 values ranging form 16 nM for LNCAP to 130 nM for K562. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ID8 cells NHT1d|VRem:uaX\ldoF1cW:wIHHzd4F6 M2HrU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTWQ5KGOnbHzzMEBKSzVyPUegcm0> MWexO|EzOzh{MR?=
Sf9 cells NFXlfGtHfW6ldHnvckBie3OjeR?= NFjDS4VKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIN6[2yrbjDBM2NFUzJiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2xNkBvVQ>? NFn2Z3IyPzlyNEO2Oi=>
LNCaP human prostate carcinoma cell MoH4VJJwdGmoZYLheIlwdiCjc4PhfS=> MXnJcohq[mm2aX;uJI9nKEyQQ3HQJIh2dWGwIIDyc5N1[XSnIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36= M{myVVEzOTlyM{Gz
HCT116/VP35 human colon carcinoma cell NUHnOWlGWHKxbHnm[ZJifGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKEiFVEGxOk9XWDN3IHj1cYFvKGOxbH;uJINiemOrbn;tZUBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9NVchdk1? NXfkWVYxOTJzOUCzNVM>
HCT116 human colon carcinoma cell NFvjNFFRem:uaX\ldoF1cW:wIHHzd4F6 MnfOTY5pcWKrdHnvckBw\iCKQ2SxNVYhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD1zODDuUS=> NID4SWwyOjF7MEOxNy=>
HCT116/VM46 human colon carcinoma cell Mmi2VJJwdGmoZYLheIlwdiCjc4PhfS=> NF:3XmhKdmirYnn0bY9vKG:oIFjDWFEyPi:YTUS2JIh2dWGwIHPvcI9vKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OjFibl2= M{K4cVEzOTlyM{Gz
human A2780 cells M4fCNmN6fG:2b4jpZ:Kh[XO|YYm= M4m5OFI1KGh? NFnwOWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVI{KG6P M{fJ[VI{OzBzN{[3
MCF7 cells NIjuPZdRem:uaX\ldoF1cW:wIHHzd4F6 NXn1SpE6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOS0Z5IHPlcIx{NCCLQ{WwQVI3KG6P NF\rfJEyPzF{M{iyNS=>
human MRC5 cells M1nMdWN6fG:2b4jpZ:Kh[XO|YYm= MYW3NkBp MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;Mkigcm0> NIXGV5ozOzNyMUe2Oy=>
human A2780 cells NY\iT4ZkS3m2b4TvfIlkyqCjc4PhfS=> NHHzNYs4OiCq MlzvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2yPUBvVQ>? M4rhe|I{OzBzN{[3
human A2780 cells NHzMZlZEgXSxdH;4bYPDqGG|c3H5 M1LwSVQ5KGh? NGLnTINEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVMyKG6P NXrhOGd2OjN|MEG3Olc>
A2780/DDP-R human ovarian carcinoma cell NYXNZZM3WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKEF{N{iwM2RFWC2UIHj1cYFvKG:4YYLpZY4h[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0{QCCwTR?= M2j0flEzOTlyM{Gz
human MRC5 cells MofZR5l1d3SxeHnjxsBie3OjeR?= MlLVOFghcA>? NFLRW45EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9N|khdk1? Mn;pNlM{ODF5Nke=
ABAE human fibroblast cell NIr4VmNRem:uaX\ldoF1cW:wIHHzd4F6 NGS2U4tKdmirYnn0bY9vKG:oIFHCRWUhcHWvYX6g[oljem:kbHHzeEBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OFUhdk1? M1HrVlEzOTlyM{Gz
HL60 human leukemia cell M2LhUnBzd2yrZnXyZZRqd25iYYPzZZk> Mo[wTY5pcWKrdHnvckBw\iCKTE[wJIh2dWGwIHzleYtmdWmjIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD12NjDuUS=> MV[xNlE6ODNzMx?=
human MRC5 cells M1TGRmN6fG:2b4jpZ:Kh[XO|YYm= MXeyOEBp MnnMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUS5JI5O NFH4[ZMzOzNyMUe2Oy=>
Hs 27 human fibroblast cell Mof6VJJwdGmoZYLheIlwdiCjc4PhfS=> MkDnTY5pcWKrdHnvckBw\iCKczCyO{BpfW2jbjDmbYJzd2KuYYP0JINmdGxicILvcIln\XKjdHnvckwhUUN3ME21NUBvVQ>? NGrSTo4yOjF7MEOxNy=>
CCRF-CEM human leukemia cell M33PWHBzd2yrZnXyZZRqd25iYYPzZZk> MUXJcohq[mm2aX;uJI9nKEOFUl[tR2VOKGi3bXHuJIxmfWunbXnhJINmdGxicILvcIln\XKjdHnvckwhUUN3ME21NkBvVQ>? MV2xNlE6ODNzMx?=
OVCAR-3 human ovarian carcinoma cell NWi1SYFCWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKE:YQ1HSMVMhcHWvYX6gc5ZiemmjbjDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUW0JI5O M4C1[lEzOTlyM{Gz
A2780/DDP-S human ovarian carcinoma cell NWL0R2NyWHKxbHnm[ZJifGmxbjDhd5NigQ>? M17QZmlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWOgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTV4IH7N NVrTNGRFOTJzOUCzNVM>
human HMEC1 cells NF\jV5REgXSxdH;4bYPDqGG|c3H5 M4DpblI1KGh? NFjNUWFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVYyKG6P M2WxZlI{OzBzN{[3
human HMEC1 cells NEDDPWxEgXSxdH;4bYPDqGG|c3H5 M4P0[FQ5KGh? M1fQTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhOTUNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9OlIhdk1? MUKyN|MxOTd4Nx?=
A2780/TAX-S human ovarian carcinoma cell MmHPVJJwdGmoZYLheIlwdiCjc4PhfS=> NVjRSHI1UW6qaXLpeIlwdiCxZjDBNlc5OC:WQWitV{BpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NkWgcm0> NWnKV3l3OTJzOUCzNVM>
LS174T human colon carcinoma cell MnnOVJJwdGmoZYLheIlwdiCjc4PhfS=> M{fqcmlvcGmkaYTpc44hd2ZiTGOxO|RVKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NkWgcm0> MkPWNVIyQTB|MUO=
MCF-7 human breast carcinoma cell NXftflk3WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYK4XXB1UW6qaXLpeIlwdiCxZjDNR2YuPyCqdX3hckBjemWjc4SgZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME22OkBvVQ>? NFfDNnEyOjF7MEOxNy=>
human HMEC1 cells NX:0Z4prS3m2b4TvfIlkyqCjc4PhfS=> MWO3NkBp NFq3VpFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVY3KG6P MoLvNlM{ODF5Nke=
PC3 human prostate carcinoma cell NUPVOVhGWHKxbHnm[ZJifGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKFCFMzDoeY1idiCycn;zeIF1\SClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ4IH7N MVixNlE6ODNzMx?=
human A2780 cell line MVrQdo9tcW[ncnH0bY9vKGG|c3H5 M1LYZlczKGh? MmjiRY51cXC{b3zp[oVz[XSrdnWg[YZn\WO2IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdCCuaX7lJJdieyCmZYTldo1qdmWmIHnuJIEhf2ixbHWgZ4VtdCB5MjDodkBkgXSxdH;4bYNqfHliYYPzZZktKEmFNUC9O|Ehdk1? Mm\tNVUxOjd6NkO=
human ovarian (A2780) cancer cell NI\oNpBEgXSxdH;4bYPDqGG|c3H5 M1rrT2N6fG:2b4jpZ{Bm\m[nY4Sgc44hcHWvYX6gc5ZiemmjbjCoRVI4QDBrIHPhcoNmeiClZXzsJIxqdmVuIFnDOVA:PzFibl2= NFjnOZMyPTF{NUm3NS=>
MLF mouse lung fibroblast cell NYjObG9oWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFXuRXpKdmirYnn0bY9vKG:oIF3MSkBud3W|ZTDseY5oKG[rYoLvZoxie3RiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTd{IH7N M33ZNFEzOTlyM{Gz
human NCI60 cells NILRS5BRem:uaX\ldoF1cW:wIHHzd4F6 MWi3NkBp M{fWR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9O|QvPyCwTR?= NFrTWVAzOTB6MEewNy=>
LX-1 human lung carcinoma MXvQdo9tcW[ncnH0bY9vKGG|c3H5 NEXreYRKdmirYnn0bY9vKG:oIFzYMVEhcHWvYX6gcJVv\yClYYLjbY5wdWFicILvcIln\XKjdHnvckwhUUN3ME23OUBvVQ>? NEmwbG8yOjF7MEOxNy=>
A431 human squamous cell M3PTT3Bzd2yrZnXyZZRqd25iYYPzZZk> MorRTY5pcWKrdHnvckBw\iCDNEOxJIh2dWGwIIPxeYFud3W|IHPlcIwh[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF04PSCwTR?= NID0PJoyOjF7MEOxNy=>
SKBR-3 human breast carcinoma cell NEm4RnFRem:uaX\ldoF1cW:wIHHzd4F6 MWfJcohq[mm2aX;uJI9nKFONQmKtN{BpfW2jbjDidoVie3RiY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD15NzDuUS=> MXWxNlE6ODNzMx?=
A2780/TAX-R human ovarian carcinoma cell NUK3UHJbWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFXvU4pKdmirYnn0bY9vKG:oIFGyO|gxN1SDWD3SJIh2dWGwIH;2ZZJq[W5iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD15ODDuUS=> NHnMXZcyOjF7MEOxNy=>
M109 mouse lung carcinoma cell NHnNWlFRem:uaX\ldoF1cW:wIHHzd4F6 Mkf6TY5pcWKrdHnvckBw\iCPMUC5JI1wfXOnIHz1coch[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF05OCCwTR?= NUDEPWM4OTJzOUCzNVM>
CACO-2 human colon carcinoma cell MWLQdo9tcW[ncnH0bY9vKGG|c3H5 MWDJcohq[mm2aX;uJI9nKEODQ1:tNkBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTh4IH7N NU\oWIRtOTJzOUCzNVM>
A549 human lung carcinoma cell NFnXcIhRem:uaX\ldoF1cW:wIHHzd4F6 MnHqTY5pcWKrdHnvckBw\iCDNUS5JIh2dWGwIHz1coch[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF06PiCwTR?= M4LpclEzOTlyM{Gz
MIP human colon carcinoma cell NVHUVJFOTnWwY4Tpc44h[XO|YYm= MoDRTY5pcWKrdHnvckBw\iCPSWCgbJVu[W5iY3;sc44h[2G{Y3nuc41iKGOnbHygcIlv\SxiSVO1NF0xNjF{IN88US=> MVOxNlE6ODNzMx?=
K562 human leukemia cell MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 MV3Jcohq[mm2aX;uJI9nKEt3NkKgbJVu[W5ibHX1b4VucWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTBwMUOg{txO M1;tRlEzOTlyM{Gz
MCF-7 tumor cell MUfQdo9tcW[ncnH0bY9vKGG|c3H5 MUDJcohq[mm2aX;uJI9nKE2FRj23JJR2dW:{IHPlcIwheHKxbHnm[ZJifGmxbh?= M3rWR|ExQDR|MkGx
human NCI60 cells MnL0VJJwdGmoZYLheIlwdiCjc4PhfS=> NFHB[|g4OiCq MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FSU[wJINmdGy|IHHzd4V{e2WmIHHzJIxmfGijbDDl[oZm[3RiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmsJGxEPTB;MD65NFQh|ryP NH;Sd2UzOTB6MEewNy=>
PC3 cell MkfpSpVv[3Srb36gZZN{[Xl? NHLMTXBKdmirYnn0bY9vKG:oIGDDN{Bk\WyuIHPsc45w\2WwaXOgZZN{[XluIFnDOVA:OTBizszN MlLsNVExPjN4MEm=
HCT116 cell NHOyS|BHfW6ldHnvckBie3OjeR?= M2W5bmlvcGmkaYTpc44hd2ZiSFPUNVE3KGOnbHygZ4xwdm:pZX7pZ{Bie3OjeTygTWM2OD1zMzFOwG0> MX2xNVA3OzZyOR?=
A2780 cell MUDGeY5kfGmxbjDhd5NigQ>? NGDVcJdKdmirYnn0bY9vKG:oIFGyO|gxKGOnbHygZ4xwdm:pZX7pZ{Bie3Ojef-8kEBKSzVyPUG1JO69VQ>? M3nINlEyODZ|NkC5
Mia PaCa-2 cell MUTGeY5kfGmxbjDhd5NigQ>? MlPvTY5pcWKrdHnvckBw\iCPaXGgVIFE[S1{IHPlcIwh[2yxbn;n[Y5q[yCjc4PhfUwhUUN3ME2zOkDPxE1? NUXIXXQ1OTFyNkO2NFk>
human A2780 cells NE\6cGtHfW6ldHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? NXmyOnNtOTh2Nkm4NFk>
human A2780 cells MUPGeY5kfGmxbjDhd5NigQ>? NGXmfXEzPCCq MlPVTY5pcWKrdHnvckBw\iClZHutcYVlcWG2ZXSgVoIheGixc4Doc5J6dGG2aX;uJIF1KHSqckiyNUBqdiCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAzPCCqcoO= NUH4XY5FOTh2Nkm4NFk>

... Click to View More Cell Line Experimental Data

In vivo Administration of Flavopiridol at 7.5 mg/kg for 7 days displays slight antitumor activity against P388 murine leukemia, resulting in %T/C value of 110, and active against the human A2780 ovarian carcinoma implanted sc in nude mice, producing 1.5 log cell kill (LCK). [5] Flavopiridol treatment at 1-2.5 mg/kg for 10 days significantly suppresses collagen-induced arthritis in mice in a dose-dependent manner, by inhibiting synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII are maintained. [6] In the p21-intact Hct116 xenografts in nude mice, administration of CPT-11 (100 mg/kg) followed by Flavopiridol (3 mg/kg) 7 and 16 hours later significantly inhibits tumor regression by 86% and 82%, respectively, displaying >2 fold inhibition compared with CPT-11 alone by 40 %. The combination produces ~30% complete response rate (CR) in contrast to CPT-11 alone where no CR is found. [7]

Protocol

Kinase Assay:

[1]

+ Expand

CDK kinase assay:

For CDK1/cyclin B1 kinase assay, kinase reactions consist of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 (human) complex, 1 μg histone HI, 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.5 mM DTT). For CDK2/cyclin E kinase assay, kinase reactions consist of 5 ng of baculovirus expressed GST-CDK2/cyclin E (human) complex, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). For CDK4/cyclin D1 kinase assay, kinase reactions consist of 150 ng of baculovirus expressed GST-CDK4/cyclin D1 (human), 280 ng of Stag-cyclin D1, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-33P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT). Reactions are incubated for 45 minutes for CDK1 and CDK2, or 1 hour for CDK4 at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester and the filters are quantitated using a TopCount 96-well liquid scintillation counter. Flavopiridol is dissolved at 10 mM in dimethylformamide (DMF) and evaluated at six concentrations, each in triplicate. The final concentration of DMF in the assay = 2%. IC50 values are derived by nonlinear regression analysis and have a coefficient of variance = 16%. To assay Flavopiridol activity on CDK6, a filter-binding assay is established. The following are combined in the reaction mixture: 2 μL of CDK6 (0.7 mg/μL), 5 μL of histone H1 (6 mg/mL), 14 μL of kinase buffer (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phosphate, 25 mM MOPS (pH 7.0), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM Na-vanadate), 3 μL of increasing concentrations of Flavopiridol diluted in 50% DMSO, and 6 μL of 33P-ATP (1 mCi/mL) in nonradioactive ATP at 90 μM concentration (final concentration: 15 μM). The assay is initiated by the addition of 33P-ATP. The reaction is incubated for 20 minutes at 30°C. A 25 μL aliquot of the supernatant is then spotted onto Whatman P81 phosphocellulose paper. Filters are washed 5 times with 1% phosphoric acid solution. Wet filters are counted in the presence of 1 mL of scintillation fluid. Cdk9 activity is measured using 50 nM of recombinant Cdk9/cyclin T in 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 3 μM Na3VO4, 150 μM RNA polymerase CDT peptide and 80 μM ATP. Cdk7 assay is performed in the same buffer using 37 nM of purified kinase in the presence of 200 μM ATP and 10 μM myelin binding protein as a substrate. The potency of Flavopiridol toward CDK9 and CDK7 is determined using either a strong anion exchanger (Dowex 1-X8 resin, formate form)-based assay or a scintillation proximity assay. IC50 values are calculated from the dose-response curves.
Cell Research:

[5]

+ Expand
  • Cell lines: MCF-7, LNCAP, PC3, HCT116, CACO-2, A549, HL60, K562 cells and et al.
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Flavopiridol for 72 hours at which time the tetrazolium dye, MTS in combination with phenazine methosulfate, is added. After 3 hours, the absorbency is measured at 492 nm, which is proportional to the number of viable cells. The results are expressed as IC50 values. For cell Cycle analysis, cells are fixed in paraformaldehyde and ethanol, washed, resuspended in staining solution of TdT enzyme and FITC-dUTP, washed, stained with PI following RNase treatment, and then analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female Balb/c×DBA/2J F1 mice inoculated ip with P388 ascites leukemic cells, and Balb/c nu/nu nude mice subcutaneous implanted with A2780, Br-cycE, or A431 cells
  • Formulation: Dissolved in a mixture of Cremophor/ethanol (50:50), and diluted in water
  • Dosages: ~7.5 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (37.32 mM)
Ethanol 8 mg/mL (19.9 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 401.84
Formula

C21H20ClNO5

CAS No. 146426-40-6
Storage powder
in solvent
Synonyms NSC 649890 HCl,HMR-1275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03593915 Recruiting Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2
NCT03441555 Recruiting Acute Myeloid Leukemia (AML) AbbVie|Tolero Pharmaceuticals Inc. May 30 2018 Phase 1
NCT03563560 Recruiting Acute Myeloid Leukemia Sumitomo Dainippon Pharma Co. Ltd. May 15 2018 Phase 1
NCT03298984 Recruiting Acute Myeloid Leukemia Tolero Pharmaceuticals Inc. September 25 2017 Phase 1
NCT02520011 Recruiting Acute Myeloid Leukemia Tolero Pharmaceuticals Inc. March 14 2016 Phase 2
NCT01349972 Completed Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

Related CDK Products0

Tags: buy Flavopiridol (Alvocidib) | Flavopiridol (Alvocidib) supplier | purchase Flavopiridol (Alvocidib) | Flavopiridol (Alvocidib) cost | Flavopiridol (Alvocidib) manufacturer | order Flavopiridol (Alvocidib) | Flavopiridol (Alvocidib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID